"von Willebrand Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. It functions in adhesion of platelets to collagen and hemostatic plug formation. The prolonged bleeding time in VON WILLEBRAND DISEASES is due to the deficiency of this factor.
| Descriptor ID |
D014841
|
| MeSH Number(s) |
D12.776.124.125.920 D23.119.985
|
| Concept/Terms |
von Willebrand Factor- von Willebrand Factor
- Factor VIIIR-Ag
- Factor VIIIR Ag
- Factor VIIIR-RCo
- Factor VIIIR RCo
- Ristocetin-Willebrand Factor
- Ristocetin Willebrand Factor
- von Willebrand Protein
- Factor VIII-Related Antigen
- Factor VIII Related Antigen
- Ristocetin Cofactor
|
Below are MeSH descriptors whose meaning is more general than "von Willebrand Factor".
Below are MeSH descriptors whose meaning is more specific than "von Willebrand Factor".
This graph shows the total number of publications written about "von Willebrand Factor" by people in this website by year, and whether "von Willebrand Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 3 | 3 |
| 2005 | 2 | 0 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "von Willebrand Factor" by people in Profiles.
-
Deletion of platelet CLEC-2 decreases GPIba-mediated integrin aIIbß3 activation and decreases thrombosis in TTP. Blood. 2022 04 21; 139(16):2523-2533.
-
Distribution and history of extensional stresses on vWF surrogate molecules in turbulent flow. Sci Rep. 2022 01 07; 12(1):171.
-
Von Willebrand factor: A key glycoprotein involved in thrombo-inflammatory complications of COVID-19. Chem Biol Interact. 2021 Oct 01; 348:109657.
-
Redefining outcomes in immune TTP: an international working group consensus report. Blood. 2021 04 08; 137(14):1855-1861.
-
Aberrant von Willebrand factor expression of sinusoidal endothelial cells and quiescence of hepatic stellate cells in nodular regenerative hyperplasia and obliterative portal venopathy. Histopathology. 2020 Jun; 76(7):959-967.
-
Laboratory monitoring during pregnancy and post-partum hemorrhage in women with von Willebrand disease. J Thromb Haemost. 2020 03; 18(3):604-608.
-
Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab. Am J Hematol. 2020 04; 95(4):E76-E77.
-
T cell epitope mimicry between Sjögren's syndrome Antigen A (SSA)/Ro60 and oral, gut, skin and vaginal bacteria. Clin Immunol. 2014 May-Jun; 152(1-2):1-9.
-
Identification of the thiol isomerase-binding peptide, mastoparan, as a novel inhibitor of shear-induced transforming growth factor ß1 (TGF-ß1) activation. J Biol Chem. 2013 Apr 12; 288(15):10628-39.
-
Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura. Am J Hematol. 2012 May; 87 Suppl 1:S88-91.